Infection and Metabolic Dysfunction-Associated Steatotic Liver Disease: Two Peas in a Pod

Abstract Objective Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is increasingly linked to a heightened risk of various infections, significantly impacting patient health outcomes. This review aims to explore the systemic implications of MASLD and its bidirectional relationship with infections to guide integrated management approaches. Recent Findings The rising prevalence of MASLD, driven by obesity and type 2 diabetes, has highlighted its association with compromise dysbiosis. These factors contribute to a higher risk of severe disease outcomes in patients with infections such as hepatitis B and C, HIV, COVID-19, and bacterial infections. Emerging evidence underscores a complex interplay between MASLD and infections that complicates clinical management. Summary Addressing the dual burden of MASLD and associated infections necessitates a holistic approach to enhance patient care. Future research should focus on unraveling the mechanisms underpinning these interactions and developing tailored preventive and therapeutic strategies.